Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An editorial by Head of NDORMS, Professor Andrew Carr published this week in The BMJ argues we should be doing far less knee surgeries as the procedure presents no real benefit to middle aged or older patients with persistent knee pain.

An editorial by Head of NDORMS, Professor Andrew Carr published this week in The BMJ argues we should be doing far less knee surgeries as the procedure presents no real benefit to middle aged or older patients with persistent knee pain.

linked paper in the same issue of The BMJ adds substantially to the debate by systematically reviewing all the evidence on the benefits and harms of arthroscopic knee surgery – a type of keyhole surgery – for middle aged and older adults with knee pain and degenerative knee disease. This study concluded that the benefit of surgery for these patients is inconsequential and potentially harmful. They say the benefit is “markedly smaller than that seen for exercise therapy” and their findings do not support surgery as a treatment for knee osteoarthritis.

Both articles are part of The BMJ’s Too Much Medicine campaign - to highlight the threat to human health and the waste of resources caused by unnecessary care.

Over 700,000 knee arthroscopies (a type of keyhole surgery) are carried out in the USA and 150,000 in the UK each year on middle aged and older adults with persistent knee pain. Yet the evidence for arthroscopic surgery is known to be weak, with all but one published trials showing no added benefit for surgery over control treatment. 

“It is difficult to support or justify a procedure with the potential for serious harm, even if it is rare, when that procedure offers patients no more benefit than placebo,” argues Professor Andrew Carr. “With rates of surgery at their current level, a substantial number of lives could be saved and deep vein thrombosis prevented each year if this treatment were to be discontinued or diminished”.

Professor Carr believes “we may be close to a tipping point” where the weight of evidence against arthroscopic knee surgery for pain is enough to overcome concerns about the quality of studies, bias and vested interests. When that point is reached, he concludes, “we should expect a swift reversal of established practice.”  

 

Full editorial here.
Full paper here.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.